astrazeneca glp 1 AstraZeneca’s experimental obesity pill helped patients lose up to 11.8% of their body weight in a mid-stage trial, as competition intensifies in the rapidly growing market for oral weight-loss drugs. Readout Newsletter: Abeona, Pfizer, Regeneron,

The front page had me (pulled from social media) on the cover with a headline Grant said

Read our recent blog post written by Dara Katcher Levy and Sarah Wicks where they provide some high level thoughts on the CDER ad/pro letters released yesterday

Clinical and genetic predictors of glycemic control and weight loss response to liraglutide in patients with type 2 diabetes

CNS Neurosci Ther (2015) 21:54957

Activities that engage the core and promote general movement are beneficial

Petrelintide, developed by Zealand Pharma, is a once-weekly, long-acting analog structurally similar to cagrilintide and is being evaluated in a phase 2 trial (ZUPREME-1) for obesity treatment